Stryker (SYK) Osake Kurssi
Stryker Kurssi
Viimeisten 19 vuoden aikana Strykern liikevaihto kasvoi 8,4 % vuodessa ja ylsi 25,12 Mrd. USD:een. Osakekohtainen tulos on kasvanut 8,2 % vuodessa viimeisten 19 vuoden aikana. Strykern nettomarginaali 12,9 % on noussut verrattuna 11,7 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 1,23 %. Jakosuhde on noin 40 % tuloksesta. Osinko on kasvanut 15,5 % vuodessa viimeisten 19 vuoden aikana. Strykern 12 kuukauden konsensustavoitehinta on 380,00 USD, noin yli kurssia 38,0 %. 34 analyytikosta 27 suosittaa ostoa — kokonaiskonsensus on Osta.
Stryker osakekurssi
Stryker liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Stryker -osakkeesta
The business model of Stryker Corp focuses on providing innovative medical technologies and solutions worldwide. As a leading medical technology company, Stryker Corp specializes in products and services across various segments, including orthopedics, medical and surgical, neurotechnology, and spine. With a strong emphasis on research and development, Stryker Corp strives to deliver advanced and effective healthcare solutions to improve patient outcomes. The company's commitment to innovation, quality, and customer satisfaction has made it a trusted name in the medical industry. Stryker Corp's business model revolves around leveraging its expertise and cutting-edge technologies to meet the evolving needs of healthcare professionals and enhance the lives of patients.
Stryker Corp is primarily active in the healthcare industry.
The main competitors of Stryker Corp in the market are Johnson & Johnson, Medtronic, Zimmer Biomet Holdings, and Boston Scientific.
Stryker Corp is a renowned American medical technology company established in 1941. With over 80 years of experience, Stryker has evolved into a global leader specializing in surgical equipment and orthopedic implants. The company's roots trace back to its founding by Dr. Homer Stryker, an innovative orthopedic surgeon who developed various medical devices. Today, Stryker Corp offers a wide range of products across multiple medical disciplines, including reconstructive devices, neurotechnology, spine systems, and more. The company's commitment to innovation, coupled with strategic acquisitions, has solidified its position as a trusted name in the medical industry.
Stryker Corp has achieved significant milestones throughout its history. A major accomplishment for the company was the development and introduction of the first-ever surgical navigation system, the Navigation System II. This technology revolutionized surgical procedures by providing real-time imaging and guidance to surgeons, improving precision and patient outcomes. Another notable milestone for Stryker Corp was the acquisition of Howmedica, a leading orthopedic company, in 1998. This strategic move further strengthened Stryker Corp's position in the medical technology industry, enhancing its product portfolio and global presence. Over the years, the company has continued to innovate and has been recognized for its advancements in medical devices and solutions.
Stryker Corp is primarily present in various countries and regions worldwide. Some of the key locations include the United States, where the company is headquartered in Kalamazoo, Michigan. Additionally, Stryker has a significant presence in Europe, with operations in countries such as Germany, France, the United Kingdom, Italy, and Switzerland. The company is also active in the Asia-Pacific region, specifically in countries like China, Japan, India, and Australia. With its global reach, Stryker Corp ensures its innovative medical technologies and products are available to healthcare professionals and patients across different parts of the world.
Stryker Corp represents values of innovation, integrity, and excellence in the medical technology industry. The company's corporate philosophy centers around delivering high-quality products and services that improve patient outcomes and enhance healthcare providers' capabilities. By continually investing in research and development, Stryker strives to introduce cutting-edge solutions that address critical healthcare needs and promote sustainable growth. With a commitment to ethical business practices and global collaboration, Stryker focuses on delivering value to its stakeholders, including healthcare professionals, patients, employees, and shareholders. Stryker Corp's dedication to advancing medical technology and improving lives embodies its core values and corporate philosophy.
Analyytikot asettavat tällä hetkellä Stryker-osakkeelle keskimääräisen tavoitehinnan 382,61 USD (mediaani: 380,00 USD), mikä merkitsee +38,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 34 analyytikkoarvioon.
34 analyytikkoa arvioi tällä hetkellä Stryker-osaketta: 27 suosittaa ostoa, 7 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Stryker-yhtiöltä 27,23 Mrd. USD liikevaihtoa ja 14,99 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Stryker-osake noteerataan hintaan 244,80 EUR (275,43 USD).
Stryker-osake (SYK) on listattuna 12 pörssissä, muun muassa: NYSE (SYK), London (0R2S.L), SIX (Zürich) (SYK.SW), XETRA (SYK.DE), Frankfurt (SYK.F), München (SYK.MU), Stuttgart (SYK.SG), Düsseldorf (SYK.DU).
Stryker Corp is a US-American company that specializes in the manufacturing and sale of medical devices, implantable products, and medical services. The company was founded in 1941 and has since become a leading company in the medical technology industry. Stryker has four business segments, namely Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. In the Medical Devices segment, Stryker offers a wide range of products including endoscopy devices, respiratory devices, patient monitoring devices, neurological monitoring devices, and medical lighting systems. These products are used in hospitals and clinical facilities for patient diagnosis and treatment. In Orthopedics, Stryker is one of the world leaders in implants and instruments for joint surgery. The company offers products for the hip, knee, shoulder, wrist, and other joints. Stryker has also taken a leading role in introducing robotics in surgery in this field. The Mako robot allows for precise implantations, enabling patients to have faster recovery and improved quality of life. The Medical and Surgical Instruments segment includes a wide range of instruments for surgery, including surgical saws, scalpels, forceps, and other instruments for various surgical procedures. These instruments are used by physicians for a variety of surgical interventions. In the Neurotechnology and Spine Products segment, Stryker develops and distributes products for spinal surgery, including implants for intervertebral discs and for stabilization of the cervical and lumbar spine. In addition to selling products, Stryker also offers medical services. This includes consulting and support for the implementation of products and systems in hospitals and medical facilities. Technical support and customer service are also part of the offerings. Stryker's business model is based on its ability to develop and produce innovative and high-quality products for the medical field. The company emphasizes close collaboration with medical professionals to ensure that the offered products meet the requirements of the practice and enable optimal treatment for patients. The company also strives to continuously improve its products and develop new technologies. In particular, the introduction of robotics in surgery offers Stryker significant growth opportunities as it has the potential for higher efficiency, precision, and better treatment outcomes. Overall, Stryker is a leading company in the medical technology industry, specializing in the development of innovative products and the provision of high-quality medical services. The company has a wide range of products in various business segments, including Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. Stryker's business model is based on serving medical professionals with high-quality products and services and developing innovative technologies to achieve even better treatment outcomes for patients.
odotettu liikevaihto Stryker on 27,23 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Stryker on 5,79 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Stryker:n hinta-voitto-suhde (P/E) on tällä hetkellä 18,37. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Stryker-osakkeen arvostusta.
Stryker:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,91. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Stryker-osakkeen arvostuskennuslukuna.
Stryker:n Eulpool-laatuscore on 8/10.
Stryker:n ISIN on US8636671013. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Stryker:n WKN on 864952. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Stryker:n ticker on SYK. Tämä pörssinoteeraus käytetään Stryker-osakkeiden kauppaan pörssissä.
Stryker osake
Stryker vertaisryhmä
Stryker Ticker
Stryker FIGI
Kaikki tunnusluvut ja syvällinen analyysi Stryker:sta
Meidän osakeanalyysimme Stryker-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Stryker:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: